Hepatitis C

Infectious Disease Clinics of North America

Volumn 14, Issue 3, 2000, Pages 633-667

  Cheney, Catherine Petruff ^a,c   Chopra, Sanjiv ^a,b   Graham, Camilla ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Clinical Hepatology   (United States)

^c Division of Gastroenterology   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE CONTROL; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PHYLOGENY; PREVALENCE; REVIEW; SCREENING TEST; VIRUS TRANSMISSION;

EID: 0033831510     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(05)70125-2     Document Type: Article

References (271)

1. Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first- and second-generation assays
2. Leucocytoclastic vasculitis associated with mixed cryoglobulinaemia and hepatitis C virus infection
3. Localization of hepatitis C virus in cutaneous vasculitic lesions in patients with type II cryoglobulinemia
4. A role for hepatitis C virus infection in type II cryoglobulinemia
5. Hepatitis C and inclusion body myositis
6. Analysis of the role of hepatitis C in transfusion-associated hepatitis
7. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection
8. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
9. Hepatitis C
10. Failure of ketoprofen and interferon combination therapy to improve interferon-resistant chronic hepatitis C
11. Interferon-alpha increases prostaglandin E2 production by cultured liver biopsy in patients with chronic viral hepatitis: Can nonsteroidal anti-inflammatory drugs improve the therapeutic response to interferon?
12. A double-blind, placebo-controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C
13. A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody- and hepatitis B virus DNA-positive chronic hepatitis B
14. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: A randomized clinical trial with long-term follow-up
15. Molecular cloning of a rat chromosome putative recombinogenic sequence homologous to the hepatitis B virus encapsidation signal
16. Elevated serum iron predicts poor response to interferon treatment in patients with chronic HCV infection
17. Lichen planus and chronic hepatitis C: Exacerbation of the lichen under interferon-alpha-2a therapy
18. Hepatitis C antibody prevalence in blood donors in different governorates in Egypt
19. Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: A randomized trial
20. Jaundice occurring one to four months after transfusion of blood or plasma
21. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin
22. A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis
23. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial
24. Hepatitis C virus infection in a large cohort of homosexually active men: Independent associations with HIV-1 infection and injecting drug use but not sexual behaviour
25. Analytical and laboratory evaluation of a new fully-automated third generation enzyme immunoassay for the detection of antibodies to the hepatitis C virus
26. An escalating dose regime of recombinant interferon-alpha 2A in the treatment of chronic hepatitis C
27. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: Results from a controlled randomized trial in 80 patients
28. Polymerase chain reaction for the diagnosis of hepatitis B and C viral hepatitis
29. The low risk of hepatitis C virus transmission among sexual partners of hepatitis C-infected hemophilic males: An international, multicenter study
30. Triple antiviral therapy for chronic hepatitis C in interferon-alpha non-responders: A pilot randomized controlled study
31. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C
32. Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995
33. Patient-to-patient transmission of hepatitis C virus during colonoscopy
34. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A prospective study
35. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection
36. Multicenter randomized, controlled study of intramuscular administration of interferon-beta for the treatment of chronic hepatitis C
37. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis
38. Vaccination of chimpanzees against infection by the hepatitis C virus
39. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
40. Genetic organization and diversity of the hepatitis C virus
41. The role of hepatitis C virus in fulminant viral hepatitis in an area with endemic hepatitis A and B
42. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection
43. Analysis of a successful immune response against hepatitis C virus
44. Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia
45. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis
46. Effectiveness of glycyrrhizin for oral lichen planus in patients with chronic HCV infection
47. Renal manifestations of hepatitis C infection
48. Reliability of the third-generation recombinant immunoblot assay for hepatitis C virus
49. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group
50. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group
51. Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C
52. Classification of chronic hepatitis: Diagnosis, grading and staging
53. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial
54. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis
55. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial
56. Hepatitis C and hepatocellular carcinoma
57. Intrafamily transmission of hepatitis C virus: Sexual and non-sexual contacts
58. Clinical manifestations of hepatitis C
59. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection
60. Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: A case-control study in Italy. Brescia HCC Study
61. Lichen planus and virus C hepatitis: Disappearance of the lichen under interferon alfa therapy
62. Third-generation recombinant immunoblot assay: Comparison of reactivities according to hepatitis C virus genotype
63. Recombinant leukocyte interferon treatment of chronic hepatitis B
64. Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study
65. Transmission of hepatitis C virus by a cardiac surgeon
66. Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis
67. Risk for non-A, non-B (type C) hepatitis through sexual or household contact with chronic carriers
68. Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV)
69. Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogeneous patient population
70. Lack of protective immunity against reinfection with hepatitis C virus
71. Hepatitis C virus-associated fulminant hepatic failure
72. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization
73. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein
74. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: Results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study
75. Therapy of hepatitis C: Interferon alfa-n1 trials
76. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients
77. Hepatitis A: Detection by immune electron microscopy of a viruslike antigen associated with acute illness
78. Transfusion-associated hepatitis not due to viral hepatitis type A or B
79. Association between hepatitis C virus and mixed cryoglobulinemia
80. Milk thistle (Silybum marianum) for the therapy of liver disease
81. Management of chronic hepatitis C: Clinical audit of biopsy based management algorithm
82. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein
83. Long-term outcome of hepatitis C infection after liver transplantation
84. Viral infections in short-term injection drug users: The prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses
85. Hepatitis C - Role of perinatal transmission
86. The polymerase chain reaction and hepatitis C virus diagnosis
87. Temporal arteritis symptoms in a patient with hepatitis C virus associated type II cryoglobulinemia and small vessel vasculitis
88. Histopathology of HCV infection
89. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C
90. Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C
91. Hepatitis C infection: A rare cause of fulminant hepatic failure
92. Lack of evidence for the heterosexual transmission of hepatitis C
93. Prevention of HIV/AIDS and other blood-borne diseases among injection drug users. A national survey on the regulation of syringes and needles
94. Hepatitis C: Use and interpretation of HCV diagnostic tests in the clinical setting
95. High prevalence of diabetes mellitus in patients with chronic hepatitis C. A case-control study
96. Severe aplastic anemia associated with seronegative community-acquired hepatitis C virus infection
97. Prevalence of hepatitis C virus antibodies and cryoglobulinemia in patients with leukocytoclastic vasculitis
98. A pilot study of iron depletion as adjuvant therapy in chronic hepatitis C patients not responding to interferon
99. Relationship of aminotransferases to liver histological status in chronic hepatitis C
100. A controlled study to determine the optimal dose regimen of interferon-alpha 2b in chronic hepatitis C
101. Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C virus infection
102. Association between chronic hepatitis C infection and hepatocellular carcinoma in a Scottish population
103. Liver histology in hepatitis C infection: A comparison between patients with persistently normal or abnormal transaminases
104. Retreatment of chronic hepatitis C with consensus interferon
105. Hepatitis C: Global prevalence
106. Autoimmune thrombocytopenia associated with hepatitis C virus infection
107. Aplastic anemia and viral hepatitis. Non-A, non-B, non-C?
108. + T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection
109. Degree of diversity of hepatitis C virus quasispecies and progression of liver disease
110. Prolonged therapy of chronic hepatitis C with ribavirin
111. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report
112. Hepatitis C: The clinical spectrum of disease
113. Detection of common hepatitis C virus subtypes with a third-generation enzyme immunoassay
114. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses
115. Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma
116. Simultaneous infection with HIV and hepatitis C virus following occupational conjunctival blood exposure
117. High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C
118. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection
119. Lichen planus and hepatitis C virus-related chronic active hepatitis
120. Chronic hepatitis C without anti-hepatitis C antibodies by second-generation assay. A clinicopathologic study and demonstration of the usefulness of a third-generation assay
121. Therapy of hepatitis C: Consensus interferon trials. Consensus Interferon Study Group
122. Hepatitis C infection, cryoglobulinemia, and vasculitic neuropathy. Treatment with interferon alfa: Case report and literature review
123. Transmission of hepatitis C in an isolated area in Japan: Community-acquired infection. The South Kiso Hepatitis Study Group
124. Extrahepatic manifestations of hepatitis C and the association with alcoholic liver disease
125. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA
126. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release
127. Cytokines in viral hepatitis
128. The role of immune responses in the pathogenesis of hepatitis C virus infection
129. Performance of hepatitis C virus (HCV) antibody test systems in relation to HCV-RNA detection in the diagnosis of HCV infection
130. High malignancy of hepatocellular carcinoma in alcoholic patients with hepatitis C virus
131. Role of breast-feeding in transmission of hepatitis C virus to infants of HCV-infected mothers
132. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis
133. Studies on transmission of hepatitis C virus from mother-to-child in the perinatal period
134. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children
135. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C
136. Infrequent vertical transmission of hepatitis C virus
137. Epidemiology of hepatitis C and G in sporadic and familial porphyria cutanea tarda
138. Hepatitis C in a hemodialysis unit: Molecular evidence for nosocomial transmission
139. T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C virus infection and in healthy anti-hepatitis C virus-positive blood donors without viremia
140. Increased detection of hepatitis C virus infection in commercial plasma donors by a third-generation screening assay
141. Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. The Consensus Interferon Study Group
142. Absence of infection in breast-fed infants born to hepatitis C virus-infected mothers
143. Possible role of high-titer maternal viremia in perinatal transmission of hepatitis C virus
144. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: A randomized multicenter trial. Hepatitis Interventional Therapy Group
145. Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study
146. Diagnosis of hepatitis C
147. Endothelitis-like changes in chronic hepatitis C
148. Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus
149. HCV and diabetes mellitus: Evidence for a negative association
150. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: A multicenter randomized controlled trial from France
151. Therapy of hepatitis C: Patients with normal amino-transferase levels
152. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C
153. Hepatitis C virus core protein inhibits Fasand tumor necrosis factor alpha-mediated apoptosis via NF-kappaB activation
154. Association of diabetes mellitus and chronic hepatitis C virus infection
155. Long-term follow-up of chronic post-transfusion non-A, non-B hepatitis: Clinical and histological outcome
156. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy
157. Cryoglobulinaemic membranoproliferative glomerulonephritis and hepatitis C virus infection
158. Evaluation of liver histology, ALT elevation, and HCV RNA titer in patients with chronic hepatitis C
159. Hepatitis C virus antibodies in chronic active hepatitis: Pathogenetic factor or false-positive result?
160. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group
161. Beauty treatments and risk of parenterally transmitted hepatitis: Results from the hepatitis surveillance system in Italy
162. Anti-GOR and hepatitis C virus in autoimmune liver diseases
163. Oral lichen planus and HCV infection: A clinical evaluation of 263 cases
164. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia
165. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus
166. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response
167. Hepatitis C virus infection in medical personnel after needlestick accident
168. Positional isomers of monopegylated interferon alpha-2a: Isolation, characterization, and biological activity
169. Intravenous natural beta-interferon in white patients with chronic hepatitis C who are nonresponders to alpha-interferon
170. Serum HCV-RNA and liver histologic findings in patients with long-term normal transaminases
171. Renal failure associated with hepatitis C virus infection. Improvement in renal function after treatment with interferon-alpha
172. Factors predicting progression to cirrhosis and hepatocellular carcinoma in patients with transfusion-associated hepatitis C virus infection
173. Development and exacerbation of oral lichen planus during and after interferon therapy for hepatitis C
174. Histological improvement of oral Lichen planus in patients with chronic hepatitis C treated with interferon
175. Serum hepatitis C virus RNA quantity and histological features of hepatitis C virus carriers with persistently normal ALT levels
176. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy
177. Prognosis of chronic hepatitis C: Results of a large, prospective cohort study
178. Multicenter study of hepatitis C virus infection in chronic hemodialysis patients and hemodialysis center staff members
179. Progression of type C chronic hepatitis to liver cirrhosis and hepatocellular carcinoma - Its relationship to alcohol drinking and the age of transfusion
180. Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy
181. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group
182. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources
183. Interferon treatment of porphyria cutanea tarda associated with chronic hepatitis type C
184. Differences in hypervariable region 1 quasispecies of hepatitis C virus in human serum, peripheral blood mononuclear cells, and liver
185. Amantadine monotherapy in patients with chronic hepatitis C
186. Transmission of the hepatitis C virus in an hemodialysis unit: Evidence for nosocomial infection
187. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C
188. Resolution of acute hepatitis C after therapy with natural beta interferon
189. The effect of iron depletion on the response to interferon treatment in patients with chronic hepatitis C. Pilot study
190. Comparison of risk factors for hepatitis C and hepatitis B virus infection in homosexual men
191. Serosurvey of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among hospital-based surgeons. Serosurvey Study Group
192. A pilot study of recombinant interleukin-2 for treatment of chronic hepatitis C
193. Immunological disorders in C virus chronic active hepatitis: A prospective case-control study
194. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories
195. Genetic heterogeneity and properties of hepatitis C virus
196. Hepatitis C virus infection in dialysis and renal transplantation
197. Clinical efficacy of intramuscular human interferon-beta vs interferon-alpha 2b for the treatment of chronic hepatitis C
198. Acute non-A, non-B hepatitis with serum sickness-like syndrome and aplastic anemia
199. The role of liver biopsy in hepatitis C
200. Hepatitis C infection in transplantation
201. Posttransfusional, LKM-1-autoantibody-positive hepatitis C virus infection, cryoglobulinemia, and aplastic anemia
202. Binding of hepatitis C virus to CD81
203. Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: A comparison between immunocompetent and immunocompromised patients
204. Lack of evidence for a role of HCV in hepatitis-associated aplastic anaemia
205. Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication
206. Low risk of vertical transmission of hepatitis C virus by breast milk
207. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
208. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)
209. Long-incubation post-transfusion hepatitis without serological evidence of exposure to hepatitis-B virus
210. Exacerbation of lichen planus during interferon alfa-2a therapy for chronic active hepatitis C
211. The hepatitis C virus: Overview
212. Antiphospholipid antibody syndrome associated with hepatitis C infection
213. Successful cyclophosphamide treatment of cryoglobulinemic membranoproliferative glomerulonephritis associated with hepatitis C virus infection
214. Detection of occult low-grade b-cell non-Hodgkin's lymphoma in patients with chronic hepatitis C infection and mixed cryoglobulinemia
215. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention
216. Iron overload in patients with chronic viral hepatitis: How common is it?
217. Histological damage in chronic hepatitis C is not related to the extent of infection in the liver
218. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: Cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells
219. Quasispecies of hepatitis C virus in serum and in three different parts of the liver of patients with chronic hepatitis
220. Lichen planus and hepatitis C virus: Prevalence and clinical presentation of patients with lichen planus and hepatitis C virus infection
221. Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis
222. Response to high-dose interferon-alpha after failure of standard therapy in MPGN associated with hepatitis C virus infection
223. Transmission of hepatitis C via blood splash into conjunctiva
224. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis
225. The pathology of hepatitis C
226. New perspectives in the diagnosis of hepatitis C
227. A role for chronic hepatitis C virus infection in a patient with cutaneous vasculitis, cryoglobulinemia, and chronic liver disease. Effective therapy with interferon-alpha
228. Dramatic resolution of skin lesions associated with porphyria cutanea tarda after interferon-alpha therapy in a case of chronic hepatitis C
229. Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial
230. A controlled, randomized, multicenter, descending dose phase II trial of pegylated interferon alpha-2a (PEG) vs. standard interferon alpha-2a (IFN) for the treatment of chronic hepatitis C
231. Use of high-dose interferon in the treatment of chronic hepatitis C
232. Alfa interferon treatment of hepatitis C virus RNA-positive patients with normal or near-normal alanine aminotransferase levels
233. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region
234. High prevalence of hepatitis C virus infection in diabetic patients
235. Treatment of chronic hepatitis C with amantadine
236. The NS5A protein of hepatitis C virus partially inhibits the antiviral activity of interferon
237. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis
238. Hepatitis C virus associated membranous glomerulonephritis
239. Natural course of chronic hepatitis C
240. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C
241. Effects of interferon beta on non-A, non-B acute hepatitis: A prospective, randomized, controlled-dose study. Japan Acute Hepatitis Cooperative Study Group
242. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile
243. Clinical and histopathologic analysis of the relationship between lichen planus and chronic hepatitis C
244. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein
245. Viral hepatitis in health care personnel at The Johns Hopkins Hospital. The seroprevalence of and risk factors for hepatitis B virus and hepatitis C virus infection
246. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and Infants Transmission Study
247. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore - An analysis of 309 sex partnerships
248. National surveillance of dialysis associated diseases in the United States, 1995
249. Increased risk of maternal-infant hepatitis C virus transmission for women coinfected with human immunodeficiency virus type 1. Italian Study Group for HCV Infection in Children
250. Effect of daily administration period of natural alpha-interferon in patients with chronic hepatitis C
251. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy
252. Effect of iron depletion on long-term response to interferon-alpha in patients with chronic hepatitis C who previously did not respond to interferon therapy
253. T cell mechanisms in the immunopathogenesis of viral hepatitis B and C
254. Shaving as potential source of hepatitis C virus infection
255. Hepatitis C - Diagnosis and monitoring
256. Association between hepatitis C virus and non-Hodgkin's lymphoma, and effects of viral infection on histologic subtype and clinical course
257. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: Retrospective cohort study
258. Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam
259. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus
260. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: Potential role in chronic HCV infections
261. Hepatitis C virus infection among patients attending a clinic for sexually transmitted diseases
262. Amantadine is not effective in clearing HCV from the serum in patients who are not candidates for interferon therapy
263. Antigen-specific cytokine response to hepatitis C virus core epitopes in HIV/hepatitis C virus-coinfected patients
264. Hepatitis C virus infection and membrano-proliferative glomerulonephritis in Japan
265. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee
266. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy
267. Hepatitis C virus core protein enhances NF-kappaB signal pathway triggering by lymphotoxin-beta receptor ligand and tumor necrosis factor alpha
268. Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferon
269. Aplastic anemia and non-A, non-B hepatitis
270. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C
271. Hepatitis C virus causing non-A, non-B hepatitis in plasmapheresis centre